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1. Introduction
The oestrogen receptor (ER) is present in over 80% of
women with breast cancer. The majority (80%) of ER-
positive breast cancers are progesterone receptor (PR)-
positive. In this extended abstract, we provide evidence
regarding the current prognostic value of PR-expression
in ER-positive breast cancer patients. We also show
some of our own data in ER-positive breast cancers
regarding tumour characteristics by PR-status. We note
that an absent PR in ER-positive women predicts for
nodal status only in women under the age of 50 years.
A signiﬁcant proportion of women with an ER-
positive breast cancer do not respond to endocrine
therapy such as ovarian suppression, tamoxifen or
aromatase inhibitors. The presence of PR in women with
an ER-positive breast cancer supposes that oestrogens
regulate tumour growth through an intact ER-pathway
which may imply that endocrine therapy works better
than when the PR is not expressed. Is PR of any
additional value in predicting the patient’s response to
hormonal therapy in women with an ER-positive breast
cancer?
2. PR: Independent prognostic marker in breast cancer?
Results from the National Surgical Adjuvant Breast
and Bowel Project (NSABP) and other large studies
compared untreated womenwith an ER-negative tumour
and those with an ER-positive breast cancer. Those with
anER-positive tumour have a longer disease-free survival
(DFS) of approximately 10% at 5 years [1]. The same
authors found that PR is a better predictor of response to
hormonotherapy than ER. This is understandable be-
cause almost all women with a PR-positive tumour also
express ER [2] which may imply that the ER-positive/PR-
negative group is less sensitive to anti-oestrogens. The
ER-positive/PR-negative phenotype is more likely to be
seen for tumours with a high tumour grade and high
proliferative activity. This group has an intermediate
survival that is between the rate observed for women with
a positive or negative expression of both the ER and PR,
independent of the therapy received [3,4]. This implies
there are, based on the joint ER/PR status, probably 3
prognostic groups that have a worsening outcome from
ER+PR+, ER+PR- to ER-PR- (ER-PR+ patients only
account for approximately 1–2% of the entire popula-
tion).When other prognostic markers are considered, not
all of the studies agree that PR has an independent
prognostic value. This is because tumour grade and other
markers for aggressive tumour behaviour, like S-phase
fraction, outweigh a negative PR status as negative
prognostic predictors in women with an ER-positive
breast cancer [5,6,7]. Furthermore, longer follow-up stu-
dies show that the DFS and overall survival (OS) curves
merge for the diﬀerent prognostic groups of ERPR.
Bardou and colleagues [8], in a recently published long-
term follow-up study, reported on 2811 untreated women
with an ER-positive, node-negative or node-positive
breast cancer and concluded, from multivariate analyses,
that the purely prognostic signiﬁcance of PR among ER-
positive patients forDFS andOS is extremelymodest and
probably only relevant in the short-term.
3. PR: An age-dependent prognostic eﬀect?
In a series of 1473 primary breast cancers operated
upon between 2000 and 2003, we assessed whether
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patient and tumour characteristics in ER-positive breast
cancers diﬀer according to their PR-status. We excluded
women with invasive lobular carcinomas, those receiv-
ing neoadjuvant therapy and those with an ER-negative
breast cancer (n = 470). Women with an ER-positive/
PR-negative breast cancer (n = 239) were older, more
likely to have a high grade tumour and more likely to be
HER-2/neu-overexpressors than those with PR expres-
sion. Women with PR-negative tumours had no diﬀer-
ences in their tumour size or nodal status and the
quantitative values of ER were not lower. However, our
ﬁndings indicate that the prognostic signiﬁcance of an
absent PR may be age-related. In the small group of
women under the age of 50 years with an ER-positive/
PR-negative breast cancer (12.8%), an absent PR pre-
dicted for a positive lymph node status in low grade
tumours (P = 0.03). In a multivariate analysis, PR re-
mained an independent predictor for lymph node status
in women under the age of 50 years, but with less power
than for other predictors like tumour size and grade. A
negative PR in an ER-positive breast cancer can be ex-
plained by lower circulating oestrogen levels that are no
longer capable of inducing PR, but also by a defective
ER-pathway. The age-dependent prognostic role of the
PR can be explained by this mechanism. In younger
women, the PR depends on ovarian oestrogens and an
absent PR is more likely to reﬂect a defective oestrogen-
responsive pathway than in older women where an ab-
sent PR is a natural variant because of low circulating
oestrogens. We have no data on whether this loco-
regional aggressiveness for an absent PR is reﬂected in a
poorer outcome by age. A treatment independent
prognostic eﬀect for the PR will remain unknown be-
cause almost all women receive some form of adjuvant
treatment.
4. PR: Is it predictive for response to hormonal therapy?
If an ER-positive breast cancer does not express
PR, this may reﬂect that this tumour uses other
pathways for growth than oestrogens alone. This may
also implicate a lack of response to anti-oestrogens.
Quantitative values of ER and PR have been reported
to be predictive for a response to hormonal therapy;
the higher the values, the better the response. How-
ever, few data are available on the eﬀect of an absent
PR as a predictor in women with an ER-positive
breast cancer. In the metastatic setting, there is one
large prospective study conﬁrming a better overall
response rate, a longer time-to-treatment failure and
longer survival for tamoxifen users if the PR is also
expressed. However, with longer follow-up, the eﬀect
of PR status disappears [9,10]. There are no data for a
predictive role of PR status when using aromatase
inhibitors in the metastatic setting. Whereas PR has
only short-term prognostic value in women with an
ER-positive breast cancer, recent evidence shows that
PR is a long-term predictor for response to tamoxifen
in the adjuvant setting. In 19 451 node-negative breast
cancer patients in the Surveillance, Epidemiology and
End-Results (SEER) database, Anderson and collea-
gues [11] examined breast cancer-speciﬁc survival ac-
cording to the ER/PR status. In the short-term, DFS
and OS curves between PR-positive and PR-negative
women diverged on tamoxifen treatment. Women with
an ER-positive/PR-positive breast cancer did better
than those with an ER-positive/PR-negative tumour
and, according to another database, PR was also
predictive in the longer-term [8]. When ranking tu-
mours from good to worse for ER+PR+ to ER+PR-
to ER-PR+ to ER-PR-, the Early Breast Cancer
Trialists’ Collaborative Group (EBCTCG) observed
relative improvements from tamoxifen treatment in
early-stage breast cancer, but only for recurrence and
not for survival [12]. This may be because PR was
measured in many diﬀerent laboratories. In the Bar-
dou paper [8], all PR assays were performed at central
laboratories with stringent quality control measures.
Preliminary analysis suggests that the presence of PR
may be the best available marker for an eﬀect of
anti-oestrogens when comparing tamoxifen with ana-
strazole in the adjuvant setting. In the Arimidex,
tamoxifen, alone or in combination (ATAC) trial,
women with an ER-positive/PR-negative breast can-
cer, after adjustment for nodal status, tumour size and
grade, had clearly more beneﬁt from anastrazole than
from tamoxifen [13]. This indicates that the predictive
role of PR is less important when using an aromatase
inhibitor than tamoxifen at baseline. In women al-
ready on tamoxifen for 2 years, Ferno and colleagues
[14] found that another 3 years of tamoxifen was not
eﬀective if the PR is absent; Coombs and colleagues
[15] found that exemestane is better than tamoxifen in
this situation, and also if the PR was expressed, as has
been found for switching to anastrazole in a smaller
study of high-risk women [16].
5. Conclusions
PR has a short-term prognostic value in the group of
women with an ER-positive breast cancer. The age-re-
lated prognostic value of PR as a predictor for nodal
status in women under the age of 50 years needs further
exploration. The DFS and OS curves for patients
grouped according to PR status diverge for patients on
tamoxifen treatment. Aromatase inhibitors work better
than tamoxifen in women with an ER-positive breast
cancer when the PR is not expressed. In women on ta-
moxifen for 2 years, aromatase inhibitors work better in
any PR-phenotype group at least for control of DFS.
P. Neven et al. / EJC Supplements Vol 2 No. 9 (2004) 46–48 47
References
1. Clark GM, McGuire WL. Steroid receptors and other prognostic
factors in primary breast cancer. Semin Oncol 1988, 15S1, 15–20.
2. Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS.
Progesterone receptors as a prognostic factor in Stage II breast
cancer. N Engl J Med 1983, 309, 1343–1347.
3. Fisher ER, Sass R, Fisher B. Pathologic ﬁndings from the national
surgical adjuvant breast project. Correlations with concordant and
discordant oestrogen and progesterone receptors. Cancer 1987, 59,
1554–1559.
4. Wenger CR, Beardslee S, Owens MA, et al. DNA ploidy: S-phase,
and steroid receptors in more than 127,000 breast cancer patients.
Breast Cancer Res Treat 1993, 28, 9–20.
5. Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of
oestrogen or progesterone receptor and pathologic characteristics
of diﬀerentiation as indicators of prognosis in node negative breast
cancer patients: ﬁndings from National Surgical Adjuvant Breast
and Bowel Project Protocol B-06. J Clin Oncol 1988, 6,1076–1087.
6. Robertson JF, Cannon PM, Nicholson RI, Blamey RW. Oestrogen
and progesterone receptors as prognostic variables in hormonally
treated breast cancer. Int J Biol Markers 1996, 11, 29–35.
7. Hawkins RA, White G, Bundred NJ. Prognostic signiﬁcance of
oestrogen and progestogen receptor activities in breast cancer. Br J
Surg 1987, 74, 1009–1013.
8. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM.
Progesterone receptor status signiﬁcantly improves outcome predic-
tion over oestrogen receptor status alone for adjuvant endocrine
therapy in two large breast cancer databases. J Clin Oncol 2003, 21,
1973–1979.
9. Ravdin PM, Green S, Dorr TM. Prognostic signiﬁcance of
progesterone receptor levels in oestrogen receptor-positive patients
with metastatic breast cancer treated with tamoxifen: results of a
prospective Southwest Oncology Group study. J Clin Oncol 1992,
10, 1284–1291.
10. Elledge RM, Green S, Pugh R et al. Oestrogen receptor (ER) and
progesterone receptor (PgR), by ligand-binding assay compared
with ER, PgR and pS2, by immuno-histochemistry in predicting
response to tamoxifen in metastatic breast cancer: a Southwest
Oncology Group Study. Int J Cancer 2000, 89, 111–117.
11. Anderson WF, Chu KC, Chatterjee N, Brawley O, Brinton LA.
Tumor variants by hormone receptor expression in white patients
with node-negative breast cancer from the Surveillance, Epidemiol-
ogy, and End Results Database. J Clin Oncol 2001, 19, 18–27.
12. Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for
early breast cancer: an overview of the randomised trials. Lancet
1998, 351, 1451–1467.
13. DowsettMon behalf of theATACTrialists’ Group.Analysis of time
to recurrence in the ATAC trial according to oestrogen and
progesterone receptor status. In: Proceedings from the 26th annual
SanAntonio Breast Cancer Symposium.December 2003,Abstract 4.
14. Ferno M, Stal O, Baldetorp B et al. Results of two or ﬁve years of
adjuvant tamoxifen correlated to steroid receptor and S-phase
levels. South Sweden Breast Cancer Group, and South-East
Sweden Breast Cancer Group. Breast Cancer Res Treat 2000, 59,
69–76.
15. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of
exemestane after two to three years of tamoxifen therapy in
postmenopausal women with primary breast cancer. N Engl J Med
2004, 350, 1081–1092.
16. Boccardo F, Rubagotti A, Amoroso D et al. Anastrazole appears
to be superior to tamoxifen in women already receiving adjuvant
tamoxifen treatment. In: Proceedings from the 26th annual San
Antonio Breast Cancer Symposium. December 2003, Abstract 3.
48 P. Neven et al. / EJC Supplements Vol 2 No. 9 (2004) 46–48
